Please confirm topic selection

Are you sure you want to trigger topic in your Anconeus AI algorithm?

Please confirm action

You are done for today with this topic.

Would you like to start learning session with this topic items scheduled for future?

Images
https://upload.orthobullets.com/topic/4092/images/17_moved.JPG
https://upload.orthobullets.com/topic/4092/images/dfaaba93-571e-4ef0-a484-a476cffe0e84_jss-02-03-185-f1.jpg
https://upload.orthobullets.com/topic/4092/images/calf pseudohypertrophy.jpg
https://upload.orthobullets.com/topic/4092/images/dystrophin_stains_moved.jpg
  • Summary
    • Duchenne Muscular Dystrophy presents in young males between the ages of 2 and 6 years with progressive muscle weakness.
    • It is caused by an X-linked recessive mutation leading to the absence of dystrophin protein.
    • Labs demonstrated markedly elevated CPK leves and diagnosis is made with DNA testing for dystrophin.
    • Treatment involves a multidisciplinary approach to address cardiomyopathy, pulmonary dysfunction, scoliosis, and foot deformities. 
  • Epidemiology
    • Most common hereditary neuromuscular disease
      • first described by Guillaume-Benjamin-Amand Duchenne de Boulogne, a French neurologist who first described the condition in 1861
    • Prevalence 
      • 2-3/10,000
    • Demographics
      • affects young males only
      • age of symptom onset is between 2-6 years of age
  • Etiology
    • Pathophysiology
      • dystrophin absence leads to
        • loss of DGC leading to excessive membrane fragility and permeability
        • dysregulation of calcium homeostasis
        • oxidative damage
        • poor muscle fiber regeneration
        • progressive replacement of muscle tissue with fibrous and fatty tissue
      • skeletal and cardiac muscle lose elasticity and strength
    • Genetics
      • Xp21.2 dystrophin gene defect due to point deletion and nonsense mutation
      • one third of cases result from spontaneous mutations
      • carrier females typically unaffected, however 2.5-20% of female carriers may still show symptoms
    • Associated conditions
      • orthopaedic manifestations
        • calf pseudohypertrophy
        • scoliosis
        • equinovarus foot deformity
        • joint contractures
      • nonorthopaedic conditions
        • cardiomyopathy
        • static encephalopathy

  • Physical Exam
    • Symptoms
      • early development
        • typically normal within first few years
        • delayed milestones
        • slower growth velocity
        • may present with mild hypotonia or poor head control
      • progressive weakness affecting proximal muscles first (begins with gluteal muscle weakness)
      • gait abnormalities begin around age 2 to 3 years
        • delayed walking
        • toe walking
        • clumsy, waddling gait
        • difficulty climbing stairs, hopping, or jumping
      • decreased motor skills
      • mild intellectual impairment
      • pharyngeal weakness
        • aspiration, nasal regurgitation of liquids, and nasal quality of voice
      • less common presentations
        • incontinence of urine and stool (late manifestation)
        • malignant hyperthermia
    • Physical exam
      • calf pseudohypertrophy (infiltration of normal muscle with connective tissue)
      • deep tendon reflexes present (unlike spinal muscular atrophy)
      • contractures
        • elbows, hips, knees, ankles
      • lumbar lordosis
        • compensates for gluteal weakness
      • neurogenic scoliosis
      • Gower's sign
        • rises by walking hands up legs to compensate for gluteus maximus and quadriceps weakness
      • Trendelenburg gait
      • fractures
        • frequent falls
  • Evaluation
    • Muscle biopsy
      • connective tissue infiltration and foci of necrosis
      • muscle fiber necrosis with mononuclear cell infiltrate
      • absent dystrophin with staining
    • DNA testing
      • shows absent or near-absent dystrophin protein
        • typically <5% of normal quantity of dystrophin
    • EMG
      • myopathic
        • decreased amplitude, short duration, polyphasic motor
        • normal conduction velocities
  • Imaging
    • Radiographs
      • usually to characterize fractures due to multiple falls
      • nonspecific features
        • translucent soft tissues (fatty muscle replacement)
        • scoliosis
        • hypoinflated lungs
        • cardiomegaly
    • Echocardiogram
      • dilated cardiomyopathy
        • present in all patients by late teens/early 20s
  • Differential 
      • Similarity and Distinguishing features of differential diagnosis
      • Similar traits to Duchenne's
      • Distinguishing traits from Duchenne's
      • Becker's
      • Calf pseudohypertrophy
      • Markedly elevated CPK
      • X-linked transmission
      • Becker's has slower progression of weakness with diagnosis made later (~8 yrs) and longer life expectancy
      • Prone to cardiomyopathy
      • Dystrophin decreased instead of absent due to in-frame mutation
      • Spinal muscular atrophy
      • Proximal weakness
      • Onset of weakness is earlier in childhood
      • Absent deep tendon reflexes and fasciculations
      • CPK levels are normal
      • Pseudohypertrophy is absent
      • Emery-Dreifuss dystrophy
      • Similar clinical picture
      • No calf pseudohypertrophy
      • CPK levels near normal
      • Elbow and ankle contractures develop early
      • Limb girdle dystrophy
      • Progressive motor weakness
      • No calf pseudohypertrophy
      • CPK levels are only mildly elevated
      • Guillain-Barre syndrome
      • Acute onset of weakness
      • Absent deep tendon reflexes
      • CPK levels are normal
      • CSF fluid analysis is diagnostic
  • Scoliosis
    • Introduction
      • considered a neurogenic curve
      • curve progresses rapidly from age 13 to 14 years
        • begins with mild hyperlordosis
        • progresses 1° to 2° per month starting at age 8 to 10 years
        • patients may become bedridden by age 16
      • cardiac and pulmonary function studies should be obtained pre-operatively as significant declines in function of both organ systems may make spinal fusion too high-risk
      • treatment is complicated by restrictive pulmonary disease (significant decrease in forced vital capacity)
  • Equinovarus Foot
    • Introduction
      • common foot deformity seen with Duchenne muscular dystrophy
    • Pathoanatomy
      • muscle imbalance secondary to muscle replacement with fibrofatty tissue
    • Diagnosis
      • made upon clinical exam
    • Treatment
      • nonoperative
        • stretching, physical therapy, and night time AFO use
      • operative
        • Tendinoachilles lengthening with posterior tibialis tendon transfer, toe flexor tenotomies
  • Prognosis
    • Historical prognosis
      • Most unable to ambulate independently by age 10
      • Most wheelchair dependent by age 15
      • Most die from respiratory weakness or cardiomyopathy by age 20
      • 5-, 10, and 15-year survival rates without steroid therapy
        • 100%, 72.1%, 27.9%
    • With >1 year of steroid treatment
      • Delays loss of ambulation by 3-4 years
      • Delays loss of hand to mouth function by 5 years
      • Delays loss of distal hand function by 6-8 years
flashcard locked
Create a free account or log in to see the cards.
Question
1 of 25
Pediatrics | Duchenne Muscular Dystrophy
  • Pediatrics
  • - Duchenne Muscular Dystrophy
17:24 min
10/16/2019
906 plays
5.0
  • star icon star icon star icon
  • star icon star icon star icon
  • star icon star icon star icon
  • star icon star icon star icon
  • star icon star icon star icon
(1)
Private Note